RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY
A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 01. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LOZANO DUBERNARD BERNARDO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-01, Last update posted on www.tib.eu: 2024-02-28, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
WO2023042181 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016996135 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016996135 | ||
| 003 | DE-627 | ||
| 005 | 20240308102032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230614s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016996135 | ||
| 035 | |a (EPA)WO2023042181 | ||
| 035 | |a (EPA)85602516 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LOZANO DUBERNARD BERNARDO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-01, Last update posted on www.tib.eu: 2024-02-28, Last updated: 2024-03-08 | ||
| 520 | |a A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SOTO PRIANTE ERNESTO |4 aut | |
| 700 | 0 | |a SARFATI MIZRAHI DAVID |4 aut | |
| 700 | 0 | |a CHAGOYA CORTES HECTOR ELIAS |4 aut | |
| 700 | 0 | |a LOPEZ MACIAS CONSTANTINO III ROBERTO |4 aut | |
| 700 | 0 | |a PALESE PETER |4 aut | |
| 700 | 0 | |a GARCIA-SASTRE ADOLFO |4 aut | |
| 700 | 0 | |a KRAMMER FLORIAN |4 aut | |
| 700 | 0 | |a SUN WEINA |4 aut | |
| 700 | 0 | |a TORRES ROJAS MARTHA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 01. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/85602516/publication/WO2023042181A1?q=WO2023042181 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 02 | ||